CompletedNCT00545675
Aripiprazole added to divalproex for 24-week bipolarity treatment
About this title
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
Read the official source — NCT00545675Medication studyAges 18–65South Korea
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- SeoulSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 146
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00545675
- Official title
Show the full official title
Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote
Get this study by email
Recruitment & locations
CompletedSeoul
Questions about this study
Who is behind this study?
The study sponsor is Korea Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Abilify(aripiprazole) and Depakote (divalproate).
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
